Topcon DRI OCT-1 Optical Coherence Tomography System for the Acquisition of Retinal Thickness Measurements and Ocular Images of the Posterior Chamber: Agreement and Precision Study
Collecte de données
Données recueillies dès le début de l'étude - ProspectiveCohorte
Suivi d'un groupe de personnes dans le temps pour mieux comprendre les causes et l'évolution d'une maladie.Résumé
Date de début de l'étude : 25 février 2013
Date à laquelle le premier participant a commencé l'étude.To demonstrate clinical substantial equivalence of DRI OCT-1 as comparable to the commercially available Cirrus
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.87 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Cohorte
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 18 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Critères
Inclusion Criteria for Normal Group Subjects 18 years of age or older on the date of informed consent Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent Subjects presenting at the site with normal eyes (eyes without pathology) IOP ≤ 21 mmHg bilaterally BCVA 20/40 or better bilaterally Both eyes must be free of eye disease Exclusion Criteria for Normal Group Subjects unable to tolerate ophthalmic imaging Subject with ocular media not sufficiently clear to obtain acceptable OCT images HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT 'Outside Normal Limits' and/or PSD < 1% HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses > 33% or false positives > 25%, or false negatives > 25% Presence of any ocular pathology except for cataract Previous ocular surgery or laser treatment other than uncomplicated refractive procedure or cataract surgery performed within six months prior to study scanning Narrow angle History of leukemia, dementia or multiple sclerosis Concomitant use of hydroxychloroquine and chloroquine Inclusion Criteria for Glaucoma Group Subjects 18 years of age or older on the date of informed consent Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent Subjects presenting at the site with glaucoma BCVA 20/40 or better in the study eye HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT 'Outside Normal Limits' and/or PSD < 1% in the study eye Exclusion Criteria for Glaucoma Group Subjects unable to tolerate ophthalmic imaging Subject with ocular media not sufficiently clear to obtain acceptable OCT images HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as fixation losses > 33% or false positives > 25%, or false negatives > 25% in the study eye Presence of any ocular pathology except glaucoma in the study eye Previous ocular surgery or laser treatment other than uncomplicated procedures performed within six months prior to study scanning in the study eye History of leukemia, dementia or multiple sclerosis Concomitant use of hydroxychloroquine and chloroquine Inclusion Criteria for Retina Disease Group Subjects 18 years of age or older on the date of informed consent Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent Subjects presenting at the site with retinal disease IOP <= 21 mmHg in the study eye BCVA 20/400 or better in the study eye Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others Exclusion Criteria for Retinal Disease Group Subjects unable to tolerate ophthalmic imaging Subject with ocular media not sufficiently clear to obtain acceptable OCT images Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g., cornea pathology) in the study eye Previous ocular surgery or laser treatment other than uncomplicated procedures performed within six months prior to study scanning in the study eye Narrow angle in the study eye History of leukemia, dementia or multiple sclerosis Concomitant use of hydroxychloroquine and chloroquine
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.3 groupes d'intervention sont désignés dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Objectifs de l'étude
Objectifs principaux
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 3 sites
Murray Fingeret
Jamaica, United StatesVitreous Retina Macula Consultants of New York
New York, United States